1. Aukland K, Bower BF, Berliner RW (1964) Measurement of local blood flow with hydrogen gas. Circ Res 14: 164–187
2. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77: 1761–1767
3. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW, Madara K, Longo DL (1993) Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 53: 2204–2207
4. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829–1834
5. Dowlati A, Robertson K, Cooney M, Petrons WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408–3416